倍他司汀或前庭康复（ Tetrax 生物反馈）对梅尼埃病患者生活质量和跌倒风险的影响。
The benefits of betahistine or vestibular rehabilitation (Tetrax biofeedback) on the quality of life and fall risk in patients with Ménière's disease.
机构信息
Department of Otolaryngology, Head and Neck Surgery, the Second Affiliated Hospital of Nanchang University, China.
出版信息
J Laryngol Otol. 2020 Dec;134(12):1073-1076. doi: 10.1017/S0022215120002509. Epub 2020 Dec 7.
OBJECTIVE
This study aimed to evaluate the benefits of betahistine or vestibular rehabilitation (Tetrax biofeedback) on the quality of life and fall risk in patients with Ménière's disease.
METHODS
Sixty-six patients with Ménière's disease were randomly divided into three groups: betahistine, Tetrax and control groups. Patients' Dizziness Handicap Index and Tetrax fall index scores were obtained before and after treatment.
RESULTS
Patients in the betahistine and Tetrax groups showed significant improvements in Dizziness Handicap Index and fall index scores after treatment versus before treatment (p < 0.05). The improvements in the Tetrax group were significantly greater than those in the betahistine group (p < 0.05).
CONCLUSIONS
Betahistine and vestibular rehabilitation (Tetrax biofeedback) improve the quality of life and reduce the risk of falling in patients with Ménière's disease. Vestibular rehabilitation (Tetrax biofeedback) is an effective management method for Ménière's disease.
目的
本研究旨在评估倍他司汀或前庭康复（ Tetrax 生物反馈）对梅尼埃病患者生活质量和跌倒风险的益处。
方法
66 例梅尼埃病患者随机分为倍他司汀组、 Tetrax 组和对照组。治疗前后分别采用眩晕残障程度评定量表（ Dizziness Handicap Index ， DHI ）和 Tetrax 跌倒指数（ Tetrax fall index ， TFI ）评估患者的生活质量和跌倒风险。
结果
倍他司汀组和 Tetrax 组患者治疗后 DHI 和 TFI 评分均显著低于治疗前（ p < 0.05 ）， Tetrax 组的改善程度显著优于倍他司汀组（ p < 0.05 ）。
结论
倍他司汀和前庭康复（ Tetrax 生物反馈）可改善梅尼埃病患者的生活质量，降低跌倒风险。前庭康复（ Tetrax 生物反馈）是梅尼埃病的有效治疗方法。
Zotero 插件